Moderna (TICKER: MRNA) Benchmark And Performance Data

there are 4 of samples in the benchmark for Moderna in year 2022 in 2022. The total inventory for Moderna was $47,000,000.00 in 2020. The total inventory for Moderna was $1,441,000,000.00 in 2021. The total inventory for Moderna was $0.00 in 2019. The total inventory for Moderna was $0.00 in 2018. The total inventory for Moderna was $0.00 in 2017. The sales, general, and administrative (SGA) for Moderna was $94,252,000.00 in 2018. The sales, general, and administrative (SGA) for Moderna was $64,722,000.00 in 2017. The sales, general, and administrative (SGA) for Moderna was $57,450,000.00 in 2016. The sales, general, and administrative (SGA) for Moderna was $567,000,000.00 in 2021. The sales, general, and administrative (SGA) for Moderna was $188,000,000.00 in 2020. The sales, general, and administrative (SGA) for Moderna was $110,000,000.00 in 2019. The sales, general, and administrative (SGA) for Moderna was $$1,132,000,000 in 2022. The revenue volatility for Moderna was 120.13% in 2022. The market capitalization for Moderna was $69,006,495,841.00 in 2018. The market capitalization for Moderna was $58,974,720,000.00 in 2019. The market capitalization for Moderna was $55,997,200,000.00 in 2016. The market capitalization for Moderna was $46,291,500,000.00 in 2020. The market capitalization for Moderna was $45,762,750,000.00 in 2017. The market capitalization for Moderna was $39,311,408,414.00 in 2021. The market capitalization for Moderna was $$38,552,000,000 in 2022. The gross revenue for Moderna was $48,000,000.00 in 2019. The gross revenue for Moderna was $274,000,000.00 in 2020. The gross revenue for Moderna was $176,974,000.00 in 2017. The gross revenue for Moderna was $17,736,000,000.00 in 2021. The gross revenue for Moderna was $122,512,000.00 in 2018. The gross revenue for Moderna was $101,536,000.00 in 2016. The gross revenue for Moderna was $$18,875,000,000 in 2022. The gross margin for Moderna was $49.91% in 2022. The days sales outstanding for Moderna was 44 days in 2022. The days payable outstanding for Moderna was 27 days in 2022. The days of inventory for Moderna was $81 in 2022. The cost of goods sold (COGS) for Moderna was 28.69% in 2022. The cost of goods sold (COGS) for Moderna was $8,000,000.00 in 2020. The cost of goods sold (COGS) for Moderna was $2,617,000,000.00 in 2021. The cost of goods sold (COGS) for Moderna was $0.00 in 2019. The cost of goods sold (COGS) for Moderna was $0.00 in 2018. The cost of goods sold (COGS) for Moderna was $0.00 in 2017. The cost of goods sold (COGS) for Moderna was $$5,416,000,000 in 2022. The cash to cash cycle time for Moderna was 98 in 2022. The annual percentage growth rate of Moderna was -0.06% in 2022. Moderna in its benchmark peer group, had rank 4 for cost of goods sold as a percent of revenue in 2022. Moderna in its benchmark peer group, had rank 2 for sales growth in 2022. Moderna in its benchmark peer group, had rank 2 for cash to cash cycle time in 2022. Moderna in its benchmark peer group, had rank 2 days for days of inventory in 2022. Moderna in its benchmark peer group, had rank 1 for gross revenue in 2022. Moderna in its benchmark peer group, had rank 1 days for days sales outstanding in 2022. Moderna headquarters region is East. Moderna has ticker symbol MRNA. Moderna has the following profile: Moderna, Inc. , a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.. Moderna has primary indstury Biotechnology. Moderna had a $$0 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Moderna had Regeneron Pharmaceuticals, Inc., and Incyte, and Vertex Pharmaceuticals Incorporated, and Moderna benchmark peer companies for its SIC code in 2022. Moderna had 81.65% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Moderna had 36 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Moderna had 3,900 number of employees in 2022. Moderna had 16.24% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Moderna had 13 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Moderna had 0.03% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Moderna had 0.00% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Moderna had 0 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Moderna can reduce overall cost by $$3,065,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Moderna can reduce inventory with practices including SKU Reduction in 2022. Moderna can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Moderna can reduce inventory with practices including Forecast Accuracy in 2022. Moderna can reduce inventory with practices including Demand Shaping in 2022. Moderna can reduce days sales outstanding with practices including in 2022. Moderna can increase sales revenue by $$0 improving sales performance to next benchmark tier in 2022. Moderna can increase revenue growth by $$6,000,000 by improving growth performance to next benchmark tier in 2022. Moderna can increase overall revenue by $$6,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Moderna can increase days payables outstanding with practices including Strategic Sourcing in 2022. Moderna can increase days payables outstanding by $4,266,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Moderna can improve total financial performance by $$8,024,000,000 by improving revenue, costs, and working capital in 2022. Moderna can decrease overall working capital by $$4,954,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Moderna can decrease inventory days by $688,000,000 days by reducing inventory days to next benchmark tier in 2022. Moderna can decrease days sales outstanding by $0 days by reducing days sales outstanding to next benchmark tier in 2022. Moderna can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Moderna can accelerate revenue growth practices including Pricing Optimization in 2022. Moderna can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 79 days was the measured advantage or top third performance level for days of inventory in Moderna's peer group in 2022. 7.90% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Moderna's peer group in 2022. 68 days was the measured superior or top ten performance level for days of inventory in Moderna's peer group in 2022. 62 days was the measured advantage or top third performance level for cash to cash cycle time in Moderna's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in Moderna's peer group in 2022. 52 days was the measured advantage or top third performance level for days sales outstanding in Moderna's peer group in 2022. 49.60% was the measured superior or top ten performance level for gross margin in Moderna's peer group in 2022. 47 days was the measured superior or top ten performance level for days sales outstanding in Moderna's peer group in 2022. 38.48% was the measured parity or middle performance level for sales volatility in Moderna's peer group in 2022. 34.48% was the measured advantage or top third performance level for sales volatility in Moderna's peer group in 2022. 25.42% was the measured superior or top ten performance level for sales volatility in Moderna's peer group in 2022. 12.46% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Moderna's peer group in 2022. 11.50% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Moderna's peer group in 2022. 109 days was the measured parity or middle performance level for days of inventory in Moderna's peer group in 2022. 102 days was the measured parity or middle performance level for cash to cash cycle time in Moderna's peer group in 2022. 0.15% was the measured superior or top ten performance level for sales growth in Moderna's peer group in 2022. -157 days was the measured superior or top ten performance level for cash to cash cycle time in Moderna's peer group in 2022. -0.10% was the measured parity or middle performance level for sales growth in Moderna's peer group in 2022. -0.03% was the measured advantage or top third performance level for sales growth in Moderna's peer group in 2022. $48.98% was the measured advantage or top third performance level for gross margin in Moderna's peer group in 2022. $44.95% was the measured parity or middle performance level for gross margin in Moderna's peer group in 2022. $$16,864,000,000 was the measured superior or top ten performance level for gross revenue in Moderna's peer group in 2022. $$12,843,000,000 was the measured advantage or top third performance level for gross revenue in Moderna's peer group. $$10,552,000,000 was the measured parity or middle performance level for gross revenue in Moderna's peer group in 2022.